SERA
Sera Prognostics, Inc.
Medical - Diagnostics & Research
Market Cap$73M
5Y Perf.-82.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
SERA vs OVID vs NTRA vs ACAD
Revenue, margins, valuation, and 5-year total return — side by side.
OVID
Ovid Therapeutics Inc.
Biotechnology
Market Cap$355M
5Y Perf.-26.8%
NTRA
Natera, Inc.
Medical - Diagnostics & Research
Market Cap$31.16B
5Y Perf.+91.9%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.86B
5Y Perf.+4.3%
SERA vs OVID vs NTRA vs ACAD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SERA | OVID | NTRA | ACAD |
|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Biotechnology | Medical - Diagnostics & Research | Biotechnology |
| Market Cap | $73M | $355M | $31.16B | $3.86B |
| Revenue (TTM) | $57K | $7M | $2.31B | $1.10B |
| Net Income (TTM) | $-32M | $-17M | $-208M | $376M |
| Gross Margin | -191.2% | 99.2% | 64.8% | 91.5% |
| Operating Margin | -642.4% | -5.9% | -13.4% | 7.4% |
| Forward P/E | — | — | — | 50.9x |
| Total Debt | $2M | $1M | $214M | $52M |
| Cash & Equiv. | $4M | $13M | $1.08B | $178M |
SERA vs OVID vs NTRA vs ACAD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SERA
OVID
NTRA
ACAD
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Sera Prognostics, I… (SERA) | 100 | 17.1 | -82.9% |
| Ovid Therapeutics I… (OVID) | 100 | 73.2 | -26.8% |
| Natera, Inc. (NTRA) | 100 | 191.9 | +91.9% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 104.3 | +4.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SERA vs OVID vs NTRA vs ACAD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACAD leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Ovid Therapeutics Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. NTRA also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
SERA
Sera Prognostics, Inc.
The Secondary Option
SERA lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
OVID
Ovid Therapeutics Inc.
The Growth Play
OVID is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 11.8%, EPS growth 35.1%, 3Y rev CAGR 69.0%
- Lower volatility, beta 1.45, Low D/E 1.1%, current ratio 10.91x
- 11.8% revenue growth vs SERA's 5.2%
- +8.2% vs SERA's -20.0%
Best for: growth exposure and sleep-well-at-night
NTRA
Natera, Inc.
The Income Pick
NTRA is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.26
- 20.9% 10Y total return vs ACAD's -22.9%
- Beta 1.26, current ratio 3.39x
- Beta 1.26 vs SERA's 1.56
Best for: income & stability and long-term compounding
ACAD
ACADIA Pharmaceuticals Inc.
The Value Play
ACAD carries the broadest edge in this set and is the clearest fit for value and quality.
- Better valuation composite
- 34.3% margin vs SERA's -563.9%
- 26.2% ROA vs SERA's -30.9%, ROIC 10.0% vs -46.2%
Best for: value and quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | OVID | 11.8% revenue growth vs SERA's 5.2% |
| Value | ACAD | Better valuation composite |
| Quality / Margins | ACAD | 34.3% margin vs SERA's -563.9% |
| Stability / Safety | NTRA | Beta 1.26 vs SERA's 1.56 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | OVID | +8.2% vs SERA's -20.0% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs SERA's -30.9%, ROIC 10.0% vs -46.2% |
SERA vs OVID vs NTRA vs ACAD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
FY 2018
SERA vs OVID vs NTRA vs ACAD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGOVID
Who Leads Where
ACAD leads in 2 of 6 categories
NTRA leads 1 • SERA leads 0 • OVID leads 0 • 2 tied
Explore the data ↓OVIDOvid Therapeutics Inc.
0leads
SERASera Prognostics, Inc.
0leads
NTRANatera, Inc.
1leads
ACADACADIA Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs NTRAvs SERAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
ACAD2/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NTRA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — OVID and ACAD each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NTRA is the larger business by revenue, generating $2.3B annually — 40458.1x SERA's $57,000. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to SERA's -563.9%. On growth, OVID holds the edge at +8.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SERASera Prognostics,… | OVIDOvid Therapeutics… | NTRANatera, Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $57,000 | $7M | $2.3B | $1.1B |
| EBITDAEarnings before interest/tax | -$36M | -$42M | -$310M | $96M |
| Net IncomeAfter-tax profit | -$32M | -$17M | -$208M | $376M |
| Free Cash FlowCash after capex | -$28M | -$38M | $97M | $212M |
| Gross MarginGross profit ÷ Revenue | -191.2% | +99.2% | +64.8% | +91.5% |
| Operating MarginEBIT ÷ Revenue | -642.4% | -5.9% | -13.4% | +7.4% |
| Net MarginNet income ÷ Revenue | -563.9% | -2.4% | -9.0% | +34.3% |
| FCF MarginFCF ÷ Revenue | -483.8% | -5.3% | +4.2% | +19.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | -63.2% | +8.4% | +39.8% | +9.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +15.0% | +192.3% | +185.4% | -81.8% |
Evenly matched — OVID and ACAD each lead in 3 of 6 comparable metrics.
Valuation Metrics
ACAD leads this category, winning 2 of 4 comparable metrics.
Valuation Metrics
| Metric | SERASera Prognostics,… | OVIDOvid Therapeutics… | NTRANatera, Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Market CapShares × price | $73M | $355M | $31.2B | $3.9B |
| Enterprise ValueMkt cap + debt − cash | $72M | $344M | $30.3B | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | -2.87x | -11.38x | -144.62x | 9.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 50.91x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 26.91x |
| Price / SalesMarket cap ÷ Revenue | 905.27x | 49.01x | 13.51x | 3.61x |
| Price / BookPrice ÷ Book value/share | 1.21x | 1.54x | 17.55x | 3.15x |
| Price / FCFMarket cap ÷ FCF | — | — | 285.53x | 36.74x |
ACAD leads this category, winning 2 of 4 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-41 for SERA. OVID carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to NTRA's 0.13x. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs SERA's 2/9, reflecting solid financial health.
| Metric | SERASera Prognostics,… | OVIDOvid Therapeutics… | NTRANatera, Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -41.0% | -24.0% | -15.3% | +35.6% |
| ROA (TTM)Return on assets | -30.9% | -18.6% | -10.6% | +26.2% |
| ROICReturn on invested capital | -46.2% | -36.2% | -36.1% | +10.0% |
| ROCEReturn on capital employed | -58.2% | -37.8% | -18.3% | +10.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.03x | 0.01x | 0.13x | 0.04x |
| Net DebtTotal debt minus cash | -$2M | -$12M | -$862M | -$126M |
| Cash & Equiv.Liquid assets | $4M | $13M | $1.1B | $178M |
| Total DebtShort + long-term debt | $2M | $1M | $214M | $52M |
| Interest CoverageEBIT ÷ Interest expense | -12560.33x | — | -25.21x | — |
ACAD leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NTRA five years ago would be worth $21,587 today (with dividends reinvested), compared to $1,613 for SERA. Over the past 12 months, OVID leads with a +816.7% total return vs SERA's -20.0%. The 3-year compound annual growth rate (CAGR) favors NTRA at 60.6% vs SERA's -18.1% — a key indicator of consistent wealth creation.
| Metric | SERASera Prognostics,… | OVIDOvid Therapeutics… | NTRANatera, Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -36.0% | +55.1% | -3.9% | -13.7% |
| 1-Year ReturnPast 12 months | -20.0% | +816.7% | +37.3% | +52.4% |
| 3-Year ReturnCumulative with dividends | -45.1% | -21.1% | +314.0% | +4.7% |
| 5-Year ReturnCumulative with dividends | -83.9% | -21.6% | +115.9% | +7.1% |
| 10-Year ReturnCumulative with dividends | -83.9% | -77.7% | +2089.4% | -22.9% |
| CAGR (3Y)Annualised 3-year return | -18.1% | -7.6% | +60.6% | +1.5% |
NTRA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — OVID and NTRA each lead in 1 of 2 comparable metrics.
Risk & Volatility
NTRA is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than SERA's 1.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OVID currently trades 87.9% from its 52-week high vs SERA's 46.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SERASera Prognostics,… | OVIDOvid Therapeutics… | NTRANatera, Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.56x | 1.45x | 1.26x | 1.26x |
| 52-Week HighHighest price in past year | $4.09 | $3.10 | $256.36 | $27.81 |
| 52-Week LowLowest price in past year | $1.37 | $0.27 | $131.81 | $14.45 |
| % of 52W HighCurrent price vs 52-week peak | +46.9% | +87.9% | +85.7% | +81.1% |
| RSI (14)Momentum oscillator 0–100 | 41.4 | 56.2 | 57.1 | 44.2 |
| Avg Volume (50D)Average daily shares traded | 55K | 3.5M | 1.3M | 1.8M |
Evenly matched — OVID and NTRA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: SERA as "Buy", OVID as "Buy", NTRA as "Buy", ACAD as "Buy". Consensus price targets imply 160.4% upside for SERA (target: $5) vs 19.4% for NTRA (target: $263).
| Metric | SERASera Prognostics,… | OVIDOvid Therapeutics… | NTRANatera, Inc. | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $5.00 | $3.50 | $262.50 | $34.78 |
| # AnalystsCovering analysts | 5 | 14 | 27 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). NTRA leads in 1 (Total Returns). 2 tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 2 of 6 categories
Loading custom metrics...
SERA vs OVID vs NTRA vs ACAD: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is SERA or OVID or NTRA or ACAD a better buy right now?
For growth investors, Ovid Therapeutics Inc.
(OVID) is the stronger pick with 1181% revenue growth year-over-year, versus 5. 2% for Sera Prognostics, Inc. (SERA). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Sera Prognostics, Inc. (SERA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SERA or OVID or NTRA or ACAD?
Over the past 5 years, Natera, Inc.
(NTRA) delivered a total return of +115. 9%, compared to -83. 9% for Sera Prognostics, Inc. (SERA). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus SERA's -83. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SERA or OVID or NTRA or ACAD?
By beta (market sensitivity over 5 years), Natera, Inc.
(NTRA) is the lower-risk stock at 1. 26β versus Sera Prognostics, Inc. 's 1. 56β — meaning SERA is approximately 24% more volatile than NTRA relative to the S&P 500. On balance sheet safety, Ovid Therapeutics Inc. (OVID) carries a lower debt/equity ratio of 1% versus 13% for Natera, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SERA or OVID or NTRA or ACAD?
By revenue growth (latest reported year), Ovid Therapeutics Inc.
(OVID) is pulling ahead at 1181% versus 5. 2% for Sera Prognostics, Inc. (SERA). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, OVID leads at 69. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SERA or OVID or NTRA or ACAD?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus -394. 2% for Sera Prognostics, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -450. 7% for SERA. At the gross margin level — before operating expenses — OVID leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SERA or OVID or NTRA or ACAD more undervalued right now?
Analyst consensus price targets imply the most upside for SERA: 160.
4% to $5. 00.
07Which pays a better dividend — SERA or OVID or NTRA or ACAD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is SERA or OVID or NTRA or ACAD better for a retirement portfolio?
For long-horizon retirement investors, Natera, Inc.
(NTRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Sera Prognostics, Inc. (SERA) carries a higher beta of 1. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NTRA: +20. 9%, SERA: -83. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SERA and OVID and NTRA and ACAD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SERA is a small-cap quality compounder stock; OVID is a small-cap high-growth stock; NTRA is a mid-cap high-growth stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(SERA: -63.2% · OVID: 844.7%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.